Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Abroad (travel likely)RecruitingPHASE1, PHASE2
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia · Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia · Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm · BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia · T-lymphoblastic Lymphoma · Peripheral T-cell Lymphoma
Locations
- Peking University Shenzhen Hospital, Shenzhen, Guangdong, China